Loading chat...
HI HCR174
Concurrent Resolution
Status
3/12/2021
Primary Sponsor
Ernesto Ganaden
Click for details
AI Summary
-
Department of Health must convene a Therapeutic Psilocybin Working Group to examine the medicinal and therapeutic effects of psilocybin and develop a long-term strategic plan for safe, accessible, and affordable psilocybin products for adults 21 years and older.
-
Working group shall examine federal, state, and local laws regarding therapeutic psilocybin use; medical and scientific studies on psilocybin's safety and efficacy for treating mental health conditions; and requirements for medical professionals to prescribe psilocybin.
-
Working group membership includes the Director of Health (chair), Attorney General, Dean of the John A. Burns School of Medicine at University of Hawaii, relevant legislative committee chairs, Hawaii State Council on Mental Health chair, one licensed physician or advanced practice registered nurse, and one licensed psychiatrist.
-
Preliminary report due to Legislature no later than 20 days before the 2022 Regular Session; final report with proposed legislation due no later than 20 days before the 2023 Regular Session.
-
Working group dissolved on July 1, 2023.
Legislative Description
Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Develop A Longterm Strategic Plan To Ensure The Availability Of Medicinal Psilocybin Or Psilocybin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients.
Department of Health
Last Action
Referred to HHH, FIN , referral sheet 25
3/15/2021